Warning: Undefined variable $zfal in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Deprecated: str_replace(): Passing null to parameter #3 ($subject) of type array|string is deprecated in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 530
 free
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 531
 free
 free
 
English Wikipedia
Nephropedia Template TP (
Twit Text
DeepDyve
Pubget Overpricing |  
lüll
Rituximab in indolent lymphomas Sousou T; Friedberg JSemin Hematol 2010[Apr]; 47 (2): 133-42Indolent non-Hodgkin lymphoma (NHL) comprises a group of incurable, generally slow-growing lymphomas highly responsive to initial therapy, with a relapsing and progressive course. Rituximab, an anti-CD20 antibody, has had a large impact on the treatment of indolent NHL. Its effectiveness as a single agent and in conjunction with known chemotherapy regimens has made it a standard of care in the treatment of NHL. Analysis of data obtained from NHL clinical trials, as well as data from the National Cancer Institute, indicate that the overall survival (OS) of patients with indolent NHL has improved since the discovery of rituximab. Given its effectiveness and tolerability, rituximab is currently being investigated as a maintenance agent with encouraging results. This review summarizes several landmark trials utilizing rituximab as a single agent and in combination with chemotherapy for treatment of NHL. In addition, a review of the studied rituximab maintenance dosing schedules and its impact on NHL will be presented. Overall, rituximab has changed the landscape for treatment of indolent NHL; however, additional research is necessary to identify the optimal dosing schedule, as well as patients most likely to respond to prolonged rituximab therapy.|Antibodies, Monoclonal, Murine-Derived[MESH]|Antibodies, Monoclonal/administration & dosage/*therapeutic use[MESH]|Antineoplastic Agents/administration & dosage/*therapeutic use[MESH]|Antineoplastic Combined Chemotherapy Protocols/therapeutic use[MESH]|Cancer Vaccines/therapeutic use[MESH]|Clinical Trials as Topic/statistics & numerical data[MESH]|Combined Modality Therapy[MESH]|Disease-Free Survival[MESH]|Drug Administration Schedule[MESH]|Drug Synergism[MESH]|Forecasting[MESH]|Humans[MESH]|Lymphoma, Follicular/drug therapy/immunology/mortality/therapy[MESH]|Lymphoma, Non-Hodgkin/*drug therapy/immunology/mortality[MESH]|Patient Selection[MESH]|Prognosis[MESH]|Randomized Controlled Trials as Topic/statistics & numerical data[MESH]|Rituximab[MESH]|Salvage Therapy[MESH]|Survival Rate[MESH]|Treatment Outcome[MESH]|Waldenstrom Macroglobulinemia/drug therapy[MESH] |
